drugset / Trial / NCT05207995
The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells
Phase 1/2
Completed
32 enrolled
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Belarusian State Medical University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2023-12-26
- Completion
- 2023-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Tolerogenic Dendritic Cells | Cell therapy | — | Subcutaneous |